S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Ultragenyx Pharmaceutical Stock Forecast, Price & News

-1.90 (-1.36 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $137.97
50-Day Range
MA: $145.29
52-Week Range
Now: $137.97
Volume808,528 shs
Average Volume629,283 shs
Market Capitalization$8.42 billion
P/E RatioN/A
Dividend YieldN/A
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical logo


Overall MarketRank

1.25 out of 5 stars

Medical Sector

657th out of 1,558 stocks

Pharmaceutical Preparations Industry

336th out of 638 stocks

Analyst Opinion: 2.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RARE



Sales & Book Value

Annual Sales$103.71 million
Book Value$11.32 per share


Net Income$-402,730,000.00
Net Margins-188.51%


Market Cap$8.42 billion
Next Earnings Date2/11/2021 (Estimated)
-1.90 (-1.36 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

How has Ultragenyx Pharmaceutical's stock been impacted by Coronavirus?

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RARE stock has increased by 204.2% and is now trading at $137.97.
View which stocks have been most impacted by COVID-19

Is Ultragenyx Pharmaceutical a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ultragenyx Pharmaceutical stock.
View analyst ratings for Ultragenyx Pharmaceutical
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Ultragenyx Pharmaceutical?

Wall Street analysts have given Ultragenyx Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ultragenyx Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Ultragenyx Pharmaceutical

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its earnings results on Tuesday, October, 27th. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.28) by $0.15. The biopharmaceutical company earned $81.47 million during the quarter, compared to analysts' expectations of $55.18 million. Ultragenyx Pharmaceutical had a negative net margin of 188.51% and a negative return on equity of 56.12%.
View Ultragenyx Pharmaceutical's earnings history

What price target have analysts set for RARE?

15 brokerages have issued twelve-month price objectives for Ultragenyx Pharmaceutical's shares. Their forecasts range from $64.00 to $176.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $104.69 in the next year. This suggests that the stock has a possible downside of 24.1%.
View analysts' price targets for Ultragenyx Pharmaceutical
or view Wall Street analyst' top-rated stocks.

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:
  • Dr. Emil D. Kakkis M.D., Ph.D., Pres, CEO & Director (Age 60, Pay $1.23M)
  • Mr. Thomas R. Kassberg, Chief Bus. Officer & Exec. VP (Age 60, Pay $714.84k)
  • Mr. John Richard Pinion II, Chief Quality Operations Officer & Exec. VP of Translational Sciences (Age 54, Pay $690.65k)
  • Dr. Camille L. Bedrosian, Chief Medical Officer & Exec. VP (Age 67, Pay $755.15k)
  • Ms. Mardi C. Dier, Exec. VP & CFO (Age 56)
  • Mr. Theodore A. Huizenga, VP, Corp. Controller & Principal Accounting Officer (Age 49)
  • Mr. Dennis Karl Huang, Chief Technical Operations Officer & Exec. VP (Age 55)
  • Ms. Danielle Keatley, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Karah Herdman Parschauer J.D., Gen. Counsel & Exec. VP (Age 42)
  • Mr. Ernie W. Meyer, Chief HR Officer & Exec. VP (Age 56)

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Palladiem LLC (0.00%) and Sowell Financial Services LLC (0.00%). Company insiders that own Ultragenyx Pharmaceutical stock include Camille L Bedrosian, Clay B Siegall, Emil D Kakkis, John Richard Pinion, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp and Theodore Alan Huizenga.
View institutional ownership trends for Ultragenyx Pharmaceutical

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including Sowell Financial Services LLC. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Camille L Bedrosian, Clay B Siegall, Emil D Kakkis, John Richard Pinion, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga.
View insider buying and selling activity for Ultragenyx Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was bought by a variety of institutional investors in the last quarter, including Palladiem LLC.
View insider buying and selling activity for Ultragenyx Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $137.97.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $8.42 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis. Ultragenyx Pharmaceutical employs 740 workers across the globe.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.